Case Study - AB

Below is short case summary of a 50 year old gentleman (who we shall call AB) who was very anxious about his 2021 MGUS diagnosis – what it meant for his immediate health and future management. He has kindly offered his story to be published. I thank him for his story.

AB is a 50-year-old male from Latin America with a diagnosis of IgG kappa MGUS, identified in June 2021 during a routine evaluation.

Since diagnosis, AB’s monoclonal protein levels have remained remarkably stable, ranging consistently between 0.20 and 0.25 g/dL on serum protein electrophoresis.

In June 2025, a mass spectrometry assessment detected an M-protein level of 0.064 g/dL, confirming the low and stable disease burden. His immunoglobulin levels have remained within normal ranges with no immunoparesis, and all serial laboratory evaluations—including CBC, renal function, calcium, and LDH—have been unremarkable.

No CRAB features have developed at any point.

AB maintains a strict vegan diet, exercises four times per week, and has followed a healthy lifestyle throughout the monitoring period.

Since 2023, AB has been taking Curcumin Extra Strength by BetterWay Health (4 caplets daily), each providing 1000 mg of turmeric rhizome extract (Curcuma longa) standardized to 95% curcuminoids (Curcumin C3 Complex®), plus 5 mg of black pepper fruit extract (BioPerine®) standardized to 95% piperine to enhance absorption. The product is manufactured in the USA by Sabinsa Corporation for Better Way Health.

AB specifically chose this formulation because it uses the same ingredient (Curcumin C3 Complex®) employed in published randomized clinical trial evidence in plasma cell disorders, rather than an unstandardized turmeric extract. He has maintained this specific brand and dose consistently since starting supplementation.

Regarding the apparent drop in M-protein value between AB’s earlier electrophoresis results (0.20–0.25 g/dL, 2022–2024) and the 2025 mass spectrometry result (0.064 g/dL), AB believes this reflects a difference in assay sensitivity rather than a true biological change. Capillary serum protein electrophoresis has a much higher limit of quantification than mass spectrometry, so a small, indolent, non-evolving clone may have been at a comparably low level throughout 2021–2024, simply below what the earlier method could resolve.

In that sense, the stability documented between 2021 and 2024 likely represents genuine biological quiescence rather than a technical ceiling, with the more sensitive 2025 assay potentially providing a more accurate quantitative picture of the same indolent clone rather than demonstrating regression.

Overall, AB’s condition has remained stable for four years, with no signs of progression toward smoldering or symptomatic multiple myeloma.

AB hopes others find this information helpful and plans to provide further updates as new studies are published.